One of the requirements for antitumor immunity is T cell recognition of tumor antigen peptides presented by the major histocompatibility complex (MHC), also known in humans as human leukocyte antigen (HLA), on the surface of tumor cells or antigen-presenting cells (APCs), a process known as antigen presentation. Here, HLA-C is linked to neoplasm.